RT Journal Article SR Electronic T1 Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 3191 OP 3195 DO 10.21873/anticanres.13457 VO 39 IS 6 A1 TAKESHI KOBAYASHI A1 RYO NAMITOME A1 YU HIRATA A1 MASAKI SHIOTA A1 KENJIRO IMADA A1 EIJI KASHIWAGI A1 ARIO TAKEUCHI A1 JUNICHI INOKUCHI A1 KATSUNORI TATSUGAMI A1 MASATOSHI ETO YR 2019 UL http://ar.iiarjournals.org/content/39/6/3191.abstract AB Background/Aim: To date, several serum prognostic factors have been reported in metastatic prostate cancer. In this study, we examined the prognostic value of these serum markers in Japanese men. Patients and Methods: This study included 104 patients with metastatic prostate cancer who were treated with primary androgen-deprivation therapy from 2001 to 2013. Clinicopathological factors including several serum markers were investigated for association with progression-free (PFS) and overall (OS) survival. Results: During a median follow-up of 48.1 months, median PFS and OS were 24.0 months and 67.4 months, respectively. When adjusted by age, prostate-specific antigen at diagnosis, Gleason score, and clinical stage, serum lactate dehydrogenase value was significantly associated with PFS [hazard ratio (HR)=1.42, 95% confidence interval (CI)=1.15-1.74; p=0.0004] and OS (HR=1.46, 95% CI=1.13-1.82; p=0.0014), in addition to alkaline phosphatase value for OS (HR=1.04; 95% CI=1.00-1.07; p=0.015). Conclusion: This study demonstrates the prognostic significance of alkaline phosphatase and lactate dehydrogenase values in Japanese men with de novo metastatic hormone-sensitive prostate cancer.